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Strengthening the reporting of genetic risk prediction
studies: the GRIPS statement
A Cecile JW Janssens*,1, John PA Ioannidis2,3,4,5,6, Cornelia M van Duijn1, Julian Little7 and Muin J Khoury8,
for the GRIPS Group9
The rapid and continuing progress in gene discovery for complex diseases is fueling interest in the potential application of
genetic risk models for clinical and public health practice. The number of studies assessing the predictive ability is steadily
increasing, but the quality and completeness of reporting varies. A multidisciplinary workshop sponsored by the Human Genome
Epidemiology Network developed a checklist of 25 items recommended for strengthening the reporting of Genetic RIsk
Prediction Studies, building on the principles established by previous reporting guidelines. These recommendations aim to
enhance the transparency of study reporting, and thereby to improve the synthesis and application of information from multiple
studies that might differ in design, conduct, or analysis. A detailed Explanation and Elaboration document is published on the
EJHG website.
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The recent successes of genome-wide association studies and the
promises of whole-genome sequencing fuel interests in the translation
of this new wave of basic genetic knowledge to health care practice.
Knowledge about genetic risk factors may be used to target diagnostic,
preventive, and therapeutic interventions for complex disorders based
on a person’s genetic risk, or to complement existing risk models
based on classical non-genetic factors such as the Framingham risk
score for cardiovascular disease. Implementation of genetic risk
prediction in health care requires a series of studies that encompass
all phases of translational research, starting with a comprehensive
evaluation of genetic risk prediction.
With increasing numbers of discovered genetic markers that can be
used in future genetic risk prediction studies, it is crucial to enhance
the quality of the reporting of these studies, as valid interpretation
could be compromised by the lack of reporting of key information1,2.
Information that is often missing includes details in the description
of how the study was designed and conducted (eg, how genetic
variants were selected and coded, how risk models or genetic risk
scores were constructed, and how risk categories were chosen), or how
the results should be interpreted. An appropriate assessment of the
study’s strengths and weaknesses is not possible without this informa-
tion. There is ample evidence that prediction research often suffers
from poor design and bias, and these may also have an impact on the
results of the studies and on models of disease outcomes based on
these studies.3–5 Although most prognostic studies published to date
claim signiﬁcant results,6,7 very few translate to clinically useful
applications. Just as for observational epidemiological studies,8 poor
reporting complicates the use of the speciﬁc study for research,
clinical, or public health purposes, and hampers the synthesis of
evidence across studies.
Reporting guidelines have been published for various research
designs,9 and these contain many items that are also relevant to
genetic risk prediction studies. In particular, the guidelines for genetic
association studies (STrenghtening the REporting of Genetic Associa-
tion studies (STREGA)) have relevant items on the assessment of
genetic variants, and the guidelines for observational studies
(Strengthening the Reporting of OBservational studies in Epidemio-
logy) have relevant items about the reporting of study design. The
In the recent years there has been an onslaught of publications of genetic risk factors. Besides creating signiﬁcant interest among
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www.nature.com/ejhgguidelines for diagnostic studies (STAndards for Reporting Diagnostic
accuracy (STARD)) and those for tumor marker prognostic studies
(Guidelines for Reporting of tumor MARKer studies (REMARK))
include relevant items about test evaluation; the REMARK guidelines
also have relevant items about risk prediction.10–13 However, none of
these guidelines are fully suited to genetic risk prediction studies, an
emerging ﬁeld of investigation with speciﬁc methodological issues that
need to be addressed, such as the handling of large numbers of genetic
variants (from 10s to 10000s) and ﬂexibility in handling such large
numbers in analyses. We organized a 2-day workshop with an
international group of risk prediction researchers, epidemiologists,
geneticists, methodologists, statisticians, and journal editors to
Table 1 Reporting recommendations for evaluations of risk prediction models that include genetic variants
Title and abstract
1 (a) Identify the article as a study of risk prediction using genetic factors. (b) Use recommended keywords in the abstract:
genetic or genomic, risk, prediction.
Introduction
Background and rationale 2 Explain the scientiﬁc background and rationale for the prediction study.
Objectives 3 Specify the study objectives and state the speciﬁc model(s) that is/are investigated. State if the study concerns the
development of the model(s), a validation effort, or both.
Methods
Study design and setting 4 Specify the key elements of the study design and describe the setting, locations, and relevant dates, including periods of
recruitment, follow-up, and data collection.a
Participants 5 Describe eligibility criteria for participants, and sources and methods of selection of participants.a
Variables: Deﬁnition 6 Clearly deﬁne all participant characteristics, risk factors, and outcomes. Clearly deﬁne genetic variants using a widely used
nomenclature system.a
Variables: Assessment 7 (a) Describe sources of data and details of methods of assessment (measurement) for each variable. (b) Give a detailed
description of genotyping and other laboratory methods.a
Variables: Coding 8 (a) Describe how genetic variants were handled in the analyses. (b) Explain how other quantitative variables were handled
in the analyses. If applicable, describe which groupings were chosen, and why.
Analysis: Risk model construction 9 Specify the procedure and data used for the derivation of the risk model. Specify which candidate variables were initially
examined or considered for inclusion in models. Include details of any variable selection procedures and other model-
building issues. Specify the horizon of risk prediction (eg, 5-year risk).
Analysis: Validation 10 Specify the procedure and data used for the validation of the risk model.
Analysis: Missing data 11 Specify how missing data were handled.
Analysis: Statistical methods 12 Specify all measures used for the evaluation of the risk model including, but not limited to, measures of model ﬁt and
predictive ability.
Analysis: Other 13 Describe all subgroups, interactions, and exploratory analyses that were examined.
Results
Participants 14 Report the numbers of individuals at each stage of the study. Give reasons for non-participation at each stage. Report the
number of participants not genotyped, and reasons why they were not genotyped.a
Descriptives: Population 15 Report demographic and clinical characteristics of the study population, including risk factors used in the risk modeling.a
Descriptives: Model estimates 16 Report unadjusted associations between the variables in the risk model(s) and the outcome. Report adjusted estimates
and their precision from the full risk model(s) for each variable.a
Risk distributions 17 Report distributions of predicted risks and/or risk scores.
Assessment 18 Report measures of model ﬁt and predictive ability, and any other performance measures, if pertinent.
Validation 19 Report any validation of the risk model(s).
Other analyses 20 Present results of any subgroup, interaction, or exploratory analyses, whenever pertinent.
Discussion
Limitations 21 Discuss limitations and assumptions of the study, particularly those concerning study design, selection of participants,
and measurements and analyses, and discuss their impact on the results of the study.
Interpretation 22 Give an overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar
studies, and other relevant evidence.
Generalizability 23 Discuss the generalizability and, if pertinent, the health care relevance of the study results.
Other
Supplementary information 24 State whether databases for the analyzed data, risk models, and/or protocols are or will become publicly available and if
so, how they can be accessed.
Funding 25 Give the source of funding and the role of the funders for this study. State whether there are any conﬂicts of interest.
aThese items should be reported for every population in the study.
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GENETIC RISK PREDICTION STUDIES
Genetic risk prediction studies typically develop or validate models
that predict the risk of disease, but they are also being investigated for
use in predicting prognostic outcome, treatment response, or treat-
ment-related harms. Risk prediction models are statistical algorithms,
which may be simple genetic risk scores (eg, risk allele counts), may be
based on regression analyses (eg, weighted risk scores or predicted
risks), or may be based on more complex analytic approaches such as
support vector machine learning or classiﬁcation trees. The risk
models may be based on genetic variants only, or include both genetic
and non-genetic risk factors.14
AIMS AND USE OF THE GRIPS STATEMENT
The 25 items of the GRIPS statement are intended to maximize the
transparency, quality, and completeness of reporting on research
methodology and ﬁndings in a particular study. It is important to
emphasize that these recommendations are guidelines only for how to
report research and do not prescribe how to perform genetic risk
prediction studies. The guidelines do not support oroppose the choice
of any particular study design or method, for example, the guidelines
recommend that the study population should be described, but do not
specify which population is preferred in a particular study.
The intended audience for the reporting guidelines is broad and
includes epidemiologists, geneticists, statisticians, clinician scientists,
and laboratory-based investigators who undertake genetic risk pre-
diction studies, as well as journal editors and reviewers who have to
appraise the design, conduct and analysis of such studies. In addition,
it includes ‘users’ of such studies who wish to understand the basic
premise, design, and limitations of genetic prediction studies in order
to interpret the results for their potential application in health care.
These guidelines are also intended to ensure that essential data from
future genetic risk prediction studies are presented in standardized
form, which will facilitate information synthesis as part of systematic
reviews and meta-analyses.
Items presented in the checklist are relevant for a wide array of risk
prediction studies, because GRIPS focuses on the main aspects of the
design and analysis of risk prediction studies. GRIPS does not address
randomized trials that may be carried out to test risk models, nor does
it speciﬁcally address decision analyses, cost-effectiveness analyses,
assessment of health care needs, or assessment of barriers to health
care implementation.15 Once the performance of a risk model has
been established, these next steps toward implementation require
further evaluation.10,16 For the reporting of these studies, which go
beyond the assessment of genetic risk models as such, additional
requirements apply. However, proper documentation of genetic pre-
dictive research according to GRIPS might facilitate the translation of
research ﬁndings into clinical and public health practice.
DEVELOPMENT OF THE GRIPS STATEMENT
The GRIPS statement was developed by a multidisciplinary panel of
25 risk prediction researchers, epidemiologists, geneticists, methodol-
ogists, statisticians, and journal editors, seven of whom were also part
of the STREGA initiative.11 They attended a 2-day meeting in Atlanta,
GA (USA) in December 2009 that was sponsored by the US Centers
for Disease Control and Prevention on behalf of the Human Genome
Epidemiology Network.17 Participants discussed a draft version of the
guidelines that was prepared and distributed before the meeting.
This draft version was developed on the basis of existing reporting
guidelines, namely STREGA,11 REMARK,13 and STARD.12 These were
selected out of all available guidelines (see http://www.equator-
network.org) because of their focus on observational study designs
and genetic factors (STREGA), prediction models (REMARK),
and test evaluation (REMARK and STARD). During the meeting,
methodological issues pertinent to risk prediction studies were
addressed in presentations. Workshop participants were asked to
change, combine, or delete proposed items and add additional items
if necessary. Participants had extensive post-meeting electronic corres-
pondence. To harmonize our recommendations for genetic risk
prediction studies with previous guidelines, we chose the same
wording for the items wherever possible. Finally, we tried to create
consistency with previous guidelines for the evaluation of risk
prediction studies of cardiovascular diseases and cancer.2,18 The ﬁnal
version of the checklist is presented in Table 1.
THE GRIPS EXPLANATION AND ELABORATION ARTICLE
Accompanying this GRIPS statement, an Explanation and Elaboration
document has been written (see Supplementary Text S1), modeled
after those developed for other reporting guidelines.19–22 The Expla-
nation and Elaboration document illustrates each item with at least
one published example that we consider transparent in reporting,
explains the rationale for its inclusion in the checklist, and presents
details of the items that need to be addressed to ensure transparent
reporting. The Explanation and Elaboration document was produced
after the meeting. The document was prepared by a small subgroup
and shared with all workshop participants for additional revisions and
ﬁnal approval.
CONCLUDING REMARKS AND FUTURE DIRECTIONS
High-quality reporting reveals the strengths and weaknesses of empiri-
cal studies, facilitates the interpretation of the scientiﬁc and health care
relevance of the results, especially within the framework of systematic
reviews and meta-analyses, and helps build a solid evidence base for
moving genomic discoveries into applications in health care practice.
The GRIPS guidelines were developed to improve the transparency,
quality and completeness of the reporting of genetic risk prediction
studies. As outlined in the introduction, GRIPS does not prescribe
how studies should be designed, conducted, or analyzed, and therefore
the guidelines should not be used to assess the quality of empirical
studies.23 The guidelines should be used only to check whether all
essential items are adequately reported.
Finally, the methodology for designing and assessing genetic risk
prediction models is still developing. For example, newer measures of
reclassiﬁcation were ﬁrst introduced in 2007,24 and several alternative
reclassiﬁcation measures have been proposed.25 Which measures to
apply and when to use measures of reclassiﬁcation are still subject to
ongoing evaluation and discussion.26 Furthermore, alternative strategies
for constructing risk models other than simple regression analyses are
being explored, and these may add increased complexity to the
reporting. In formulating the items of the GRIPS statement, these
methodological advances were anticipated. It is for this reason that the
GRIPS statement recommends how a study should be reported and not
how a study should be conducted or analyzed. Therefore, methodolo-
gical and analytical developments will not immediately impact the
v a l i d i t ya n dr e l e v a n c eo ft h ei t e m s ,b u tt h eG R I P Ss t a t e m e n tw i l lb e
updated when this is warranted by essential new developments in the
construction and evaluation of genetic risk models.
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